Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma.
about
Quality of life and emotional distress in advanced prostate cancer survivors undergoing chemotherapyConcurrent chemoradiation for high-risk prostate cancerTaxanes in hormone-refractory prostate cancer.Chemotherapy for patients with advanced prostate carcinoma: a new option for therapy.The treatment challenge of hormone-refractory prostate cancer.New standards in the chemotherapy of metastatic hormone-refractory prostate cancer.The experience with cytotoxic chemotherapy in metastatic castration-resistant prostate cancerDocetaxel-based regimens, the standard of care for metastatic androgen-insensitive prostate cancer.Chemotherapy for hormone-resistant prostate cancer: Where are we today?Intermittent tri-weekly docetaxel plus bicalutamide in patients with castration-resistant prostate cancer: a single-arm prospective study using a historical control for comparison.Changes in fPSA level could discriminate tPSA flare-up from tPSA progression in patients with castration-refractory prostate cancer during the initial phase of docetaxel-based chemotherapy.Vinorelbine and estramustine in androgen-independent metastatic prostate cancer: a phase II study.Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma.
P2860
Q24796034-906E530A-8A2E-4C64-9A31-3E81B966D007Q26798912-FE3D92F9-A95B-4BBA-9BB6-0D1F92D66C25Q33845088-4CCF5FBD-02B6-4BC0-B336-95140F322183Q33970538-0FB91E29-7FDD-436C-901D-78D63D6B965AQ34504202-40C343E2-83F2-46D7-8300-7738CB58A038Q36066144-BE298CFA-26C0-463D-B8F2-927CA62C9E54Q37091477-9FB95493-1CED-4BCE-850D-24DC9E4CC68BQ40340477-0F5421B1-CF44-4C28-8640-3FDE1DAD55A0Q42119686-40A9C0F0-E6A0-48C5-B729-55D503BAF68BQ42140230-7F1B8401-45D1-4FE9-8345-27D5862602EAQ43704979-626D6802-A742-4650-A106-2618CAD00688Q43781929-8DE01A74-EE29-433B-8816-31B60450765DQ43937942-AE505D2C-5451-4FC3-B814-DBAE7D555CAA
P2860
Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
Phase I trial of the combinati ...... refractory prostate carcinoma.
@en
type
label
Phase I trial of the combinati ...... refractory prostate carcinoma.
@en
prefLabel
Phase I trial of the combinati ...... refractory prostate carcinoma.
@en
P2093
P356
P1433
P1476
Phase I trial of the combinati ...... refractory prostate carcinoma.
@en
P2093
P356
10.1023/A:1008354600497
P577
1999-01-01T00:00:00Z